A federal judge in Massachusetts has denied Teva’s motion for summary judgment and granted the government’s motion for partial summary judgment in a suit alleging the pharmaceutical company caused the submission of false claims to Medicare.

According to the July 14 opinion by Judge Nathaniel M. Gorton of the U.S. District Court for the District of Massachusetts, the government contended that Teva violated the Anti-Kickback Statute (AKS) and caused the submission of false claims to Medicare under the FCA by knowingly and willfully paying Copaxone co-pays of Medicare patients via two contracted vendors and two foundations. Copaxone is used to treat multiple sclerosis.